



Chris Stemple Appointed General Manager AbbVie ANZ

AUSTRALIA, SYDNEY, December 12 2019– AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the appointment of Mr Chris Stemple to the position of General Manager Australia and New Zealand.

Chris will commence in the role late January 2020, following the announced retirement of Kirsten O’Doherty who has been in the role since 2011.

“We look forward to welcoming Chris, who will work closely together with the local management team and Kirsten in a transition over late January and February,” said Mr Frank Zhou, Vice President, JAPAC.

Chris will be based in Sydney, and joins the team following seven years in senior roles at Biogen including Managing Director ANZ since 2017.

Chris is an active advocate for the Pharmaceutical industry and innovative medicines. He is currently a board member of Medicines Australia.

Prior to his promotion at Biogen to Managing Director, he was Commercial Director where he was responsible for affiliate-wide Sales, Marketing, Regulatory and Market Access functions.

Chris has worked in a number of roles across different pharmaceutical companies including Novartis and AstraZeneca in a range of strategic business roles and therapeutic areas including neuroscience, gastroenterology, rheumatology and diabetes.

Prior to coming to Australia from Boston USA, Chris worked at Biogen Idec in R&D and as a consultant for firms Bain and Accenture.

Chris is a graduate of the Australian Institute of Company Directors, has an MBA and a Bachelor of Science – Genetics and Masters of Science from the University of Melbourne. Chris is married with three children, an Australian citizen and stalwart supporter of the AFL – The Geelong Cats!

About AbbVie in Australia

AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and



critical conditions. The company's mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience.

Our heritage in Australia reaches back more than 80 years and we employ more than 280 people with our therapies currently benefiting more than 32,000 Australians. For more information about AbbVie, please visit us at www.abbvie.com.au or follow us on [Twitter](#), [Facebook](#), [Instagram](#) or [LinkedIn](#).

###

For more Information

Lisa Maguire

MOBILE 0499 200 550

Lisa.Maguire@abbvie.com